Found: 15
Select item for more details and to access through your institution.
Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study.
- Published in:
- Brain: A Journal of Neurology, 2023, v. 146, n. 6, p. 2275, doi. 10.1093/brain/awad024
- By:
- Publication type:
- Article
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2023, v. 9, n. 4, p. 1, doi. 10.1002/trc2.12434
- By:
- Publication type:
- Article
P1‐050: ABBV‐8E12, A HUMANIZED ANTI‐TAU MONOCLONAL ANTIBODY, FOR TREATING EARLY ALZHEIMER'S DISEASE: UPDATED DESIGN AND BASELINE CHARACTERISTICS OF A PHASE 2 STUDY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P251, doi. 10.1016/j.jalz.2019.06.075
- By:
- Publication type:
- Article
O3‐09‐05: PLASMA TAU AND NEUROFILAMENT LIGHT CHAIN AS A PROGNOSTIC BIOMARKER OF DISEASE PROGRESSION IN EARLY ALZHEIMER'S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1038, doi. 10.1016/j.jalz.2018.06.2823
- By:
- Publication type:
- Article
O1‐02‐06: ABBV‐8E12, A HUMANIZED ANTI‐TAU MONOCLONAL ANTIBODY FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE: STUDY DESIGN AND BASELINE CHARACTERISTICS FOR A 96‐WEEK, MULTIPLE DOSE, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P218, doi. 10.1016/j.jalz.2018.06.2341
- By:
- Publication type:
- Article
RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO-CONTROLLED STUDY OF ABBV-8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER’S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P599, doi. 10.1016/j.jalz.2017.07.241
- By:
- Publication type:
- Article
Efficacy and safety of the alpha7 agonist ABT-126 as a monotherapy treatment in mild-to-moderate alzheimer's dementia: results of a phase 2b trial.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2014, v. 10, p. P137, doi. 10.1016/j.jalz.2014.04.081
- By:
- Publication type:
- Article
The H<sub>3</sub> antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.
- Published in:
- British Journal of Clinical Pharmacology, 2014, v. 77, n. 6, p. 965, doi. 10.1111/bcp.12281
- By:
- Publication type:
- Article
Safety, tolerability and pharmacokinetics of the histamine H<sub>3</sub> receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.
- Published in:
- British Journal of Clinical Pharmacology, 2013, v. 75, n. 5, p. 1299, doi. 10.1111/j.1365-2125.2012.04472.x
- By:
- Publication type:
- Article
A polygenic risk score (PRS) predicts cognitive decline in the APOE3 population in an early Alzheimer's disease clinical trial cohort.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.078874
- By:
- Publication type:
- Article
Apheleia‐001: A novel prescreening study designed to enrich and accelerate Alzheimer's disease clinical trials by efficiently identifying trial‐eligible participants determined to have a high probability of study inclusion, including amyloid positivity
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.074277
- By:
- Publication type:
- Article
Putting participants and study partners FIRST when clinical trials end early.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 12, p. 2736, doi. 10.1002/alz.12732
- By:
- Publication type:
- Article
Identifying predictive factors of patient dropout in Alzheimer's disease clinical trials.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.052361
- By:
- Publication type:
- Article
Baseline amyloid and tau PET imaging characteristics in the ongoing phase 2 study of tilavonemab in early Alzheimer’s disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.052183
- By:
- Publication type:
- Article
A three‐dimensional neuroimaging based deep learning model to predict Alzheimer's disease progression for clinical trial design.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.052345
- By:
- Publication type:
- Article